Introduction
Despite the fact that many patients with acute myeloid leukemia (AML) reach complete remission after chemotherapeutic treatment, many will still eventually relapse because of the persistence and subsequent outgrowth of leukemia cells that are undetectable by conventional morphological techniques. This condition is known as minimal residual disease (MRD). AML cells at diagnosis frequently display aberrant or uncommon phenotypes that allow distinction from normal hematopoietic cells and therefore can be used as immunophenotypical markers for MRD. [1] [2] [3] [4] [5] [6] [7] [8] The detection of MRD with multiparameter flowcytometry is successful in 80-90% of AML patients, while molecular techniques depending on the presence of useful chromosomal abnormalities are successful in less than 30% of AML patients. Multiparameter flow cytometry thus has great potential in MRD detection in AML. For AML it has been shown already in small studies that the presence of threshold numbers of MRD cells or the gradual increase of the frequency of MRD cells in follow-up samples correlates with relapse frequency and relapse-free survival. 7, [9] [10] [11] [12] [13] In children with acute lymphoblastic leukemia it was shown that sequential monitoring of MRD by flow cytometry provides significant prognostic information. 14 The advantages of flow cytometric analysis for detecting MRD are its relatively high sensitivity (1: to characterize cells functionally. The strategy for the immunophenotypical detection of MRD is based on the identification during follow-up, of residual leukemia cells with the same leukemia-associated phenotypes (LAPs) as established at diagnosis. To ensure that a relevant clonogenic leukemia cell population will be followed, whenever possible, primitive markers like CD34 or CD117 must be included in the LAP. [16] [17] [18] [19] Phenotypic shifts have been reported to occur after treatment. 8 Since blasts frequently display more than one LAP at diagnosis 4 as many as possible of these are applied in the MRD situation to ensure that all MRD cells are detected at followup.
The survival of leukemia cells could be due to the persistence of resistant cell subpopulations or the induction of resistant cell subpopulations during chemotherapy. Putative resistance mechanisms include (1) the presence of drug efflux pumps (P-glycoprotein (Pgp) or multidrug resistance protein (MRP) or (2) resistance due to changes in apoptotic pathways. Of these, the role of Pgp, which is an ATP-dependent membrane efflux pump, is most intensively studied. Expression and function of Pgp in de novo AML patients has been shown to be an independent adverse prognostic factor for response and survival. [20] [21] [22] [23] [24] [25] [26] Furthermore, in some studies higher Pgp expression was found in refractory and relapsed AML. 22, 24, 27 The use of rhodamine123 as Pgp probe, combined with PSC833 as Pgp inhibitor in an accumulation assay represents a sensitive and reproducible functional assay in AML both in efflux 28 and accumulation 29, 30 assay and is also applicable for frozen/thawed samples. 29 More recently, we have shown that the nucleic acid stain Syto16 combined with PSC833 is more sensitive than rhodamine123 to assess Pgp function. 31 Apart from Pgp, MRP1 (further referred to as MRP) might contribute to the multidrug resistance (MDR) phenotype in AML. 24, 25, [32] [33] [34] [35] [36] It has been shown that among others the combination of calcein-AM and probenecid can be used to detect MRP function. 37, 38 To investigate the role of Pgp and MRP in drug resistance in AML, the most informative approach would be to functionally characterize MRD cells at different stages of disease of the patient. For that purpose, MRD cells need to be identified, while in addition one should be able to determine Pgp and/or MRP function in these cells. In the present study, we developed a sensitive and reproducible four-color FACS assay that allows the simultaneous detection of Pgp or MRP function and the LAP. An accumulation assay was used with the combination Syto16/PSC833 or calcein-AM/probenecid for detection of Pgp and MRP function, respectively. The feasibility of the simultaneous detection of Pgp or MRP function with LAP is shown both in de novo AML, as well as in MRD situations. Since the use of cryopreserved samples would (1) enable enlargement of patient groups, eg in multicenter studies on MRD and (2) improve the flexibility in the laboratory, the effect of freezing in liquid nitrogen on LAP expression and Pgp/MRP function was also studied both in de novo AML and MRD material. The ability to study drug resistance at different stages of disease of an AML patient will lead to a better understanding of the role of multidrug resistance proteins in the emergence of MRD and might have consequences for chemotherapeutic strategies like multidrug resistance modulation. Further the approach presented can be extended to other mechanisms putatively involved in drug resistance in AML, like apoptotic resistance mechanisms.
Materials and methods

Reagents
RMPI 1640, Iscove's modified Dulbecco's medium and fetal calf serum (FCS) were obtained from Life Technologies (Paisley, UK), bovine serum albumin (BSA) and Hepes from ICN Biomedicals (Aurora, OH, USA), Dulbecco's minimal essential medium (DMEM) without bicarbonate and phenol red was from Flow Laboratories (Irvine, UK), phosphate buffered saline from ICN (Costa Mesa, CA, USA), Ficoll-Paque from Pharmacia Biotech (Uppsala, Sweden), 7-amino actinomycin D (7-AAD) (Via-Probe) from Pharmingen (San Diego, CA, USA), FACS lysing solution from Becton Dickinson (San Jose, CA, USA), Dimethyl sulphoxide (DMSO) and sodium azide from Merck (Darmstadt, Germany). Probenecid was obtained from Sigma (St Louis, MO, USA), Syto16 and calcein acetoxymethylester (calcein-AM) from Molecular Probes (Eugene, OR, USA), doxorubicin from Pharmacia and Upjohn BV (Woerden, The Netherlands) and colchicine from Serva Feinbiochemica (Heidelberg, Germany), while PSC833 was a gift from Novartis (Basel, Switzerland). The source of monoclonal antibodies (MoAbs) conjugated with fluorescein isothiocyanate (FITC) was as follows: CD2 and CD45 from Coulter (Coultronics, Mergency, France), CD5, CD11c, CD13 and HLADR from Dako (Glostrup, Denmark), CD7 from CLB (Amsterdam, The Netherlands), CD15, CD34 and CD61 from Becton Dickinson, CD33 from Caltag (San Francisco, CA), CD38 from Immunotech (Marseille, France), CD65 from AnderGrub (Kaumberg, Austria) and CD90 from Pharmingen. For MoAbs conjugated with phycoerythrin (PE) the source was: CD2, CD13, CD15 and CD33 from Coulter, CD7 from Immunotech, CD4, CD11b, CD34, CD38, CD56 and CD117 from Becton Dickinson, CD45 from Dako and AC133 from Miltenyi (CLB, Amsterdam, The Netherlands). The MoAbs conjugated with peridinyl chlorophyllin (PerCP) were CD45 and HLADR (Becton Dickinson) and the MoAbs conjugated with allophyocyanin (APC) were CD14, CD19, CD33, CD34, CD38, CD45 and CD117 (all Becton Dickinson).
Cell lines
The human epidermoid carcinoma cell line KB3-1 and its Pgp multidrug resistant sublines, KB8 and KB8-5, were obtained from Dr I Roninson (University of Illinois, Chicago, IL, USA; KB3-1 and KB8) or via ATCC (KB8-5). The cells were cultured in DMEM supplemented with 7.5% heat-inactivated FCS at 37°C in a humid atmosphere with 5% CO 2 . The KB8 and KB8-5 cells were cultured in the presence of 5 and 10 ng/ml colchicine, respectively. The human small-cell lung cancer cell line GLC4 and its MRP overexpressing subline GLC4-ADR were cultured in RMPI 1640 supplemented with 10% FCS. The resistant cells were cultured in the presence of 1.2 M doxorubicin. The human ovarian cancer cell line A2008 and its stable MRP transfectants MRP1-4, MRP1-6 (MRP1 clones) Leukemia and cMOAT (MRP2) (gift from Dr M Kool, Netherlands Cancer Institute, Amsterdam, The Netherlands) were cultured in RPMI 1640 supplemented with 10% FCS. All resistant cells were cultured for 7 days without drugs before experiments were performed. The cell lines were mycoplasma negative, as was tested monthly using a PCR-mediated EIA with 16S ribosomal RNA as a target.
Patients and controls
Normal bone marrow samples were obtained after informed consent from patients undergoing cardiovascular surgery. Control peripheral blood stem cells were obtained after mobilization with G-CSF, from healthy donors involved in an allogeneic peripheral blood stem cell transplantation procedure or from non-Hodgkin's lymphoma patients in complete remission. Bone marrow or peripheral blood samples from AML patients were obtained at the time of diagnosis and after treatment (BM after first, second and third course of chemotherapy, peripheral blood stem cell transplants, BM at different time points after peripheral blood stem cell transplantation), following informed consent. In the MRD study we included 127 patients thus far (73 female, 54 male) with a median age of 55 years, ranging from 15 to 75. The French-AmericanBritish (FAB) classification of the AML patients was as follows: M0 (6), M1 (12), M2 (26), M3 (7), M4 (24), M5 (26), M6 (7), RA (1), RAEB (2), RAEB-T (11), hypoplastic MDS (1), while four were not classified as caused by inadequate samples. Immunophenotypical analysis on bone marrow or peripheral blood samples from de novo AML was performed within 24 h after sampling (see establishment of leukemia-associated phenotypes). These de novo AML samples showed a median of 74% (range 24-94) blasts. For functional studies, mononuclear cells were isolated via a Ficoll gradient (1.077 g/ml) from the de novo AML sample. Erythrocytes were lysed afterwards by a 10-min incubation on ice with ammonium chloride. After this procedure, a median of 92% (range 19-100) blasts was present in these samples. The fresh mononuclear cells were tested for Pgp and MRP activity and the remaining cells were frozen in medium with 20% FCS and 10% DMSO using controlled freezing with a Kryo 10 (Planer Biomed, Sunbury, UK) and stored in liquid nitrogen. Follow-up samples were tested within 24 h after sampling for the presence of MRD cells (see MRD detection). For functional studies, erythrocytes were lysed with ammonium chloride and the fresh cells were tested for Pgp and MRP activity and the remaining cells were frozen and stored in liquid nitrogen. Frozen de novo AML or follow-up samples were rapidly thawed in a waterbath (37°C) and immediately diluted in 15 ml RPMI 1640 with 40% FCS, prewarmed to 37°C. The cells were centrifuged and resuspended in RPMI 1640 with 10% FCS for further experiments. When thawed cells were used for functional flow cytometric assays, they were preincubated for 60 min in accumulation medium (DMEM without bicarbonate and phenol red) with 40% FCS at 37°C to allow recovery of metabolic activity, 29 before resuspension in accumulation medium with 10% FCS. These cells had a median trypan blue viability of 86%.
Flow cytometry
Flow cytometry was performed using a FACScalibur (Becton Dickinson) equipped with an argon and red diode laser. When functional Pgp or MRP activity was combined with detection of leukemia-associated phenotypes, special attention had to be paid with respect to compensation of spectral overlap. 1 nM calcein-AM (fluorescence in FL1) was used for the detection of MRP function without causing problems in the FL2 channel.
Syto16 (fluorescence in FL1) showed considerable spectral overlap in FL2, which was a problem at concentrations exceeding 5 nM. Therefore, a low concentration of Syto16 (0.6 nM) was used and attention was paid to compensate FL2 fluorescence (used for PE labelled MoAbs) for the Syto16 fluorescence present in FL1. Data acquisition and analysis was performed using Cellquest software (Becton Dickinson).
Establishment of leukemia-associated phenotypes
The phenotypic analysis of de novo AML was performed on whole bone marrow or peripheral blood samples upon staining with FITC, PE, PerCP and APC conjugated MoAbs. Briefly, 0.3 × 10 6 cells in PBS with 0.1% BSA and 0.05% sodium azide (FACS buffer) were incubated in a final volume of 50 l with the appropriate combinations of MoAbs for 15 min at room temperature. Afterwards, 1 ml of FACS lysing solution was added and another 7.5 min incubation was performed at room temperature. Finally, cells were washed twice with 3 ml FACS buffer and resuspended in 0.2 ml FACS buffer.
For detailed immunophenotypical analysis of leukemia blasts, a double-step procedure was used. First, a panel of 15 quadruple MoAb combinations was used to define the immunophenotype of the blasts. In a second step, further MoAb combinations were used to assess the precise characteristics of different blast cell subpopulations. With every sample, a negative control (IgG1 isotype) and a positive control (CD45) conjugated with different fluorochromes was included to check the compensation settings of the flow cytometer. Data analysis was performed on blast cells gated with CD45dim staining and low side scatter.
MRD detection
The detection of MRD cells in follow-up material was performed on whole bone marrow or peripheral blood samples upon staining with FITC, PE, PerCP and APC conjugated MoAbs.
Cells were incubated with appropriate MoAb combinations to be able to detect cells with expression of the leukemiaassociated phenotypes found in the corresponding de novo AML. Briefly, 1.0-2.0 × 10 6 cells were incubated at a final concentration of 6 × 10 6 cells/ml FACS buffer with the appropriate combinations of MoAbs for 15 min at room temperature. Afterwards, 1 ml of FACS lysing solution was added and another 7.5 min incubation was performed at room temperature. Finally, cells were washed twice with 3 ml FACS buffer and resuspended in 0.6 ml FACS buffer. Corresponding isotype controls were included for every LAP to determine negativity and positivity for the markers tested. Data analysis was performed on blasts with CD45dim staining and SSC low properties.
Functional Pgp and MRP assay
Cells were washed in accumulation medium with 10% FCS. For Pgp function cells were incubated at a concentration of 0.3 × 10 6 cells/ml accumulation medium with 0.6 nM Syto16 with or without the Pgp inhibitor PSC833 (1 M) in a 37°C water bath and carefully shaken. After 45 min of incubation, after which for Syto16 a steady state cellular accumulation is reached, 31 the cells were immediately diluted with ice cold accumulation medium and centrifuged. For MRP function a similar protocol was followed using 1 nM calcein-AM with or without the MRP inhibitor probenecid (3 mM) in a 60-min incubation period. In both protocols the cells were resuspended in FACS buffer and kept on ice.
Pgp and MRP activities are expressed as ratios of drug fluorescence with modulator and drug fluorescence without modulator after subtraction of the fluorescence of the control (cells in accumulation medium without drugs present). The described parental and Pgp and MRP expressing sublines were used to optimise the functional Pgp and MRP assay. When using Syto16/PSC833 for detection of Pgp function in the KB3-1, KB8 and KB8-5 cells the following ratios (means ± s.d. of four experiments) were found: 0.99 ± 0.09, 2.21 ± 0.08 and 8.62 ± 0.93, respectively. In 79 de novo AML blasts tested for Pgp function a median ratio of 1.45 (range 1.0-31) was found. From CD34 + cells present in normal bone marrow samples (n = 6) a median ratio of 2.30 (range 1.73-3.73) was found while CD34
+ cells, present in peripheral blood stem cell transplants from normal allogeneic donors or non-Hodgkin's lymphoma patients in complete remission (n = 15), showed a median ratio of 6.0 (range 2.8-33).
The functional MRP assay was optimized using the MRP expressing cell lines. A 60 min accumulation assay with 1 nM calcein-AM and 3 mM probenecid showed maximal ratios. An efflux assay for 30-120 min, recommended in the literature, [38] [39] [40] in our hands did not improve the sensitivity. Moreover, since we aim at the possibility of studying small samples, as well as frozen/thawed samples with sometimes low cell yields, any procedure that omits further cell loss, such as the use of short incubation periods without extra washing steps, is preferable. For the A2008, A2008/cMOAT, A2008/MRP1-4, A2008/MRP1-6, GLC4 and GLC4/ADR the following ratios (means ± s.d.; n = 3-5) were found: 1.87 ± 0.35, 3.23 ± 0.96, 13.03 ± 1.94, 9.57 ± 0.80, 0.97 ± 0.06 and 6.18 ± 0.95, respectively. In 47 de novo AML blasts tested for MRP function a median ratio of 1.25 (range 1.0-2.29) was found. From CD34 + cells present in normal bone marrow samples (n = 3) or normal peripheral blood stem cell transplants (n = 8) a median ratio of 1.48 (range 1.44-1.52) and 1.86 (range 1.59-2.09) were found, respectively. All cell lines were used regularly to control the overall performance of the Pgp and MRP assay.
Combined detection of leukemia-associated phenotype and Pgp or MRP function
To detect Pgp or MRP function in subpopulations of blasts, cells were first loaded with the appropriate substrate/blocker combination in an accumulation assay, followed, after a washing step, by incubation with 7-AAD and appropriate PEand APC-conjugated MoAbs for detection of LAP for 30 min. The cells were kept on ice to prevent efflux of drugs. 7-AAD (10 l/10 6 cells) was included to exclude dead cells in the final analysis. The cells were washed once with 3 ml FACS buffer and resuspended in 0.2 ml FACS buffer and kept on ice until acquisition. Gating of blast cells in de novo AML and follow-up samples was performed using the LAPs that were detected at diagnosis. In our assay two channels (FL2 and FL4) were available for LAP detection, since one channel (FL1) is used for the functional Pgp or MRP assay and one channel (FL3) is used for viability staining with 7-AAD. Data analysis of control peripheral blood stem cells was performed on gated CD34 + /SSC low cells. When cells undergo a freeze-thawing procedure, a subpopulation can become apoptotic. We have shown previously, 41 that the combination of Syto16 + PSC833 and 7-AAD can be used to distinguish viable, dead, as well as early and late apoptotic CD34-positive cells. Since apoptotic and dead cells do not contain the capacity to efflux drugs, 41 these cells were always excluded from the analysis (MA van der Pol et al, manuscript in preparation).
Statistical analysis
A Spearman's rank correlation test was used to determine the correlation coefficient. Linear regression was used to determine the slope and intercept of the relationship. The Wilcoxon signed-rank test for paired samples was used with a 95% confidence interval to compare results obtained for fresh and frozen/thawed samples. Level of significance: P Ͻ 0.05.
Results
Functional characterization of MRD for Pgp and MRP function is important to explain the role of multidrug resistance in AML. In order to perform such a study, detection of leukemiaassociated phenotype (LAP) and Pgp or MRP function must be combined preferably on fresh, but if possible also on cryopreserved samples. To check the feasibility of this approach, the following questions have been addressed: (1) Which part of de novo AML samples can be characterized by LAPs for subsequent MRD detection? (2) Can Pgp and MRP activity measurements be combined with LAP detection both in de novo AML and in MRD situations? (3) What is the effect of freeze-thawing on LAP determination both in de novo AML and in MRD situations? and (4) What is the effect of freezethawing on Pgp/MRP activity combined with LAP determination both in de novo AML and in MRD situations?
Leukemia-associated phenotypes
We first examined which percentage of de novo AML samples can be characterized by one or more LAP. Blasts from 80% (102 out of 127) of AML patients displayed one or more LAP at diagnosis. Thirty-seven patients displayed one LAP, 24 patients had two, 20 patients had three and in 21 patients more than three LAPs could be established. In 67% (68 out of 102) of the patients with a LAP present on the blasts, the stem cell marker CD34 was included. If CD34 could not be detected, CD117 was used as a progenitor marker in 71% (24 out of 34) of the patients. Cross-lineage antigen expression was found in 57%, asynchronous antigen expression in 39% and clear antigen overexpression in 4% of all the LAPs found. The most frequent cross-lineage phenotype is characterized by CD7 expression on myeloid CD34 + blasts, followed by CD2-and CD19-positive phenotypes. Coexpression of CD34 and CD56 offered the most frequent asynchronous phenotype, followed by coexpression of CD34 and CD11b. Antigen overexpression was most frequently found with CD33. LAPs with CD117 as early progenitor marker were frequently of a crosslineage antigen expression type with coexpression of CD7. In Leukemia patients with LAPs present at diagnosis, the above-mentioned LAPs were used to detect MRD cells in different follow-up samples.
Simultaneous detection of Pgp or MRP function and LAP
In order to be able to determine Pgp and MRP function in MRD cells we developed a four-color FACS assay for the simultaneous detection of Pgp or MRP activity and LAP. First it was examined if the functional Pgp and MRP assay, which was performed prior to immunophenotyping, did not affect LAP expression. For 15 de novo AML samples direct immunophenotyping or immunophenotyping following incubation for Pgp and MRP activity were compared and no significant differences were found in the percentage of blasts showing a LAP (Figure 1 ), indicating that the activity assays did not alter LAP expression of de novo AML blasts.
In a similar way, 24 MRD samples were studied. As for de novo AML samples, the correlation between LAP percentages 
Comparison of LAP expression in fresh and frozen/thawed de novo AML and MRD samples
To determine if cryopreserved samples can be used for immunophenotyping studies, the most commonly found leukemiaassociated phenotypes in the group of 127 AML patients studied were compared both in fresh and frozen/thawed samples. First it was shown (Figure 4a ) that the percentage of CD34-positive blasts in the AML sample was not significantly influenced by the freeze/thawing procedure. Next, paired fresh and frozen/thawed blasts from 43 AML patients were used for LAP comparison. The expression of aberrant phenotypes was determined on CD34
+ gated blasts, in the case of CD34 + LAP Leukemia while for CD34-LAP the whole mononuclear cell fraction was used. When all samples were taken together, a very good correlation was found between fresh and frozen/thawed samples (Figure 4b ). In the upper part of Figure 5 , a representative example of cross-lineage (a, b) and asynchronous antigen (c, d) expression measured in paired fresh and frozen/thawed de novo AML blasts is shown. Although there is no obvious reason why AML blasts in a MRD situation would behave differ- ently with regard to freeze-thawing, we have nevertheless verified this in 11 MRD samples. Although a correlation exists between the percentage of CD34 + and CD117 + cells present in fresh and frozen/thawed follow-up samples clearly the % in thawed samples is higher (Figure 6a ). In contrast, LAP expression on CD117 + or CD34 + cells was not significantly different between fresh and frozen/thawed follow-up samples (Figure 6b ). Figure 5 (e-h) shows two examples of peripheral blood stem cell transplants (PBSCT), obtained in complete remission after mobilization with G-CSF, from an AML patient with a high CD34 percentage (4.09%, e) and one with a low CD34 percentage (0.57%, g). The CD34-positive cells in fresh and frozen/thawed PBSCT showed very similar expression of antigens (compare e with f and g with h).
Figure 6
Comparison of LAP expression in paired fresh and frozen/thawed MRD samples. (a) In two of the 11 follow-up samples a Ficoll procedure was performed prior to freezing the cells in liquid nitrogen. Since follow-up samples can contain large amounts of granulocytes, which can be lost by a Ficoll procedure these two samples were omitted when comparing the percentages of CD34 + and CD117 
Effect of freeze thawing on Pgp and MRP function in de novo AML and MRD
To determine if cryopreserved samples can be used to detect both Pgp and MRP function in MRD situations, fresh and frozen/thawed de novo AML samples were tested first. The effect for Pgp function was determined in 36 samples (30 de novo AML samples and six CD34
+ peripheral blood stem cell samples). The normal CD34-positive cells were included since in a MRD situation in most cases the majority of the CD34-positive cells are normal and the possibility for simultaneous measurement might be useful to further distinguish leukemia from normal cells. Results were not significantly different in fresh and frozen/thawed samples (Figure 7a) . A representative example of Pgp function tested in paired fresh and frozen/thawed samples is shown in Figure 8 , normal CD34-positive cells (a, b) and AML samples (c-f). For MRP function, 24 fresh and frozen/thawed samples were tested (19 de novo AML samples and five CD34
+ peripheral blood stem cell Leukemia P = 0.023, n = 7) function with no significant differences (Pgp, P = 0.139 and MRP, P = 0.735) between the fresh and frozen/thawed MRD values. A representative example is shown in Figure 9 . At diagnosis all the CD34 + blasts showed CD7 expression (not shown). Therefore CD34 +
CD7
+ was used as LAP to detect MRD cells and the CD34 +
− cells could be considered as normal. The Figure shows that both the percentage of CD7 + cells and Pgp and MRP activity is highly conserved upon freeze-thawing. Appropriately frozen and thawed samples thus do not differ in Pgp and MRP activity as compared to freshly investigated material both in de novo AML blasts and in MRD AML blasts.
Discussion
The detection and quantification of MRD cells enables the correlation with clinical outcome and eventually risk stratification and possibly early therapeutic intervention. The functional characterization of these MRD cells at different stages of disease in AML should give more insight into the mechanisms by which leukemia cells survive chemotherapy and eventually enable selective therapeutic intervention. The present study aimed to show the feasibility of studying Pgp and MRP activity of MRD cells identified by aberrant immunophenotypes. Essential for such a study is both the ability to identify the malignant cells in MRD situations and to detect simultaneously Pgp or MRP function.
For the detection of malignant cells the potential of leukemia-associated phenotypes (LAP) [1] [2] [3] [4] [5] [6] 8 was investigated. In 80% of the AML patients studied, we were able to establish at least one useful LAP, including in 90% of the cases CD34 or CD117 as an early marker. These LAPs can be used to detect and quantify MRD cells at follow-up, showing the potential of this approach in AML.
To study multidrug resistance in MRD, a four-color FACS assay was set up that allowed simultaneous detection of Pgp or MRP function and LAP expression. For testing Pgp or MRP function, an accumulation assay with Syto16/PSC833 and calcein-AM/probenecid has been used, respectively. Not only in a MRD situation but also in de novo AML samples tested for drug efflux activity, it is important to gate specific on the blast population since it has been reported that normal peripheral blood lymphocytes show Pgp activity. 7, 12, 13, [42] [43] [44] [45] Gating on blast cells in de novo AML samples was performed using expression of LAP. 3, 4, 6, 7, 12, 45 In our assay two channels (FL2 and FL4) were available for LAP detection, since one channel (FL1) is used for the functional Pgp or MRP assay and one channel (FL3) is used for viability staining with 7-AAD. This approach can be applied in 95% of the cases. Apart from expression of a primitive marker, like CD34 or CD117 and an aberrant marker like CD2 or CD7, blasts in de novo AML often also show expression of myeloid markers, like CD13 or CD33 and CD45dim/SSClow expression. 46 Whenever necessary or helpful, cells with LAP expression can be characterized in a separate staining including these markers. The next question concerned the possible use of cryopreserved samples.
Our results show: (1) Both in de novo AML and in MRD situations, the Pgp and MRP activity assay, which was performed prior to immunophenotyping, had no effect on the LAP expression indicating that the simultaneous detection of Pgp or MRP function with LAP can be performed without interference both in de novo and in MRD samples. (2) We have shown that both the CD34 percentage and LAP expression on CD34-positive and -negative blasts was similar in fresh and frozen/thawed AML samples. In follow-up samples the percentage of CD34 + or CD117 + cells with LAP expression was similar in fresh and frozen/thawed samples. However, the total number of MRD cells may differ as a result of the higher percentage of CD34 + or CD117 + cells found in frozen/thawed follow-up samples. The most likely explanation for the latter phenomenon is the well-known high loss of granulocytes upon freeze-thawing: a mean loss of 32% (range 15-50) of granulocytes was observed. Therefore, for MRD samples we recommend determination of the percentage of CD34 + or CD117 + cells in the fresh follow-up material, while extensive further immunophenotyping can be performed with cryopreserved material. (3) In agreement with other studies where Pgp activity was tested using accumulation or efflux assays with different combinations of substrate and modulator, 28, 29, 39, 40, 47 we showed that appropriately frozen/thawed AML samples can be used for testing Pgp activity using a sensitive accumulation assay with Syto16/PSC833 combined with LAP detection. In addition, frozen/thawed de novo AML samples were tested successfully for MRP activity combined with LAP detection. Frozen/thawed follow-up samples were successfully used to detect LAP expression together with Pgp or MRP activity.
The large supply of antibodies each labelled with different fluorochromes, as well as the different fluorescent substrates applicable for MDR activity measurements (eg Syto16 can be replaced by rhodamine 123, which is commonly used for Pgp activity detection) illustrate the flexibility of the currently described combination assay.
Altogether such an approach enables retrospective study of the frozen samples, both for the presence of MRD and for the study of multidrug resistance profiles in the course of disease. Furthermore, it enables multicenter studies on detection and quantification of MRD. Therefore, we should now be able to answer questions like: is there any evidence for chemotherapy induced selection of (sub)populations with higher levels of multidrug resistance or upregulation of Pgp and/or MRP function that might contribute to the adverse prognostic value of Pgp/MRP in AML.
Further, the approach presented can also be used to elucidate other mechanisms putatively involved in the emergence of MRD. We recently succeeded to simultaneously detect LAP expression and either apoptosis-related proteins or functional apoptosis both in newly diagnosed AML and in MRD situations (data not shown). We anticipate that such studies will be of great help to unravel the mechanisms contributing to the emergence of MRD. Such knowledge will have consequences for the development of chemotherapeutic strategies both in de novo AML, but especially in MRD situations.
